Dr Rajesh Jain, JMD
Manufacturer of pharmaceuticals, biopharmaceuticals and vaccines
B-1, Extn./G-3, Mohan Cooperative Industrial Estate, Mathura Road, New Delhi-110044
Panacea has registered a total biotech turnover of Rs 703.10 crore in 2009 with a 17 percent growth over
last fiscal. The vaccine segment of the company too has grown by 18 percent and registered a turnover of
Rs 644.40 crore. The company registered a turnover of Rs.882.30 crore in 2009-10 with a growth rate of
14 percent over last year.
The company has played a key role in eradicating polio by supplying more than 600 crore doses of oral polio
vaccine to the Government of India and UNICEF. The company has eight WHO pre-qualified vaccines including
innovative fully-liquid combination tetravalent vaccine Easyfour (DTwP-Hib) and pentavalent vaccine
Easyfive (DTwP – Hep B– Hib). It is one of the first companies to develop fully-liquid pentavalent vaccine
Easyfive (DTwP-HepB –Hib ) and bivalent OPV globally.
The pharma product portfolio of Panacea Biotec includes highly-innovative prescription products in
important therapeutic segments like pain management, diabetes and cardiovascular disease management,
renal disease management, organ transplantation, osteoporosis management, oncology and paediatric
immunization. The brands Willgo, Glizid, Glizid M, Panimum Bioral, Pangraf, Sitcom, Livoluk Fibre,
Vacosteo and Fosbait hold the top five positions in their respective therapeutic segments.
In FY 2009-10, Panacea Biotec has unveiled nine products in highly-specialized therapeutic segments in
domestic market that earned revenues of Rs 7 crore in FY 2010-11. Extensive portfolio of innovative
products is the outcome of company's focus on R&D. The specific research areas of the company are
developing new chemical entities, biological entities, novel drug delivery systems, novel therapeutic
peptides and fully-human monoclonal antibodies, vaccines and biotech-driven products.
Dr Rajesh Jain, joint managing director, Panacea Biotec, said, “We believe that innovation delivers
sustainable business value. With strong fundamentals, innovative product pipeline and increased focus
on launching products in developed markets we would be growing at a much faster pace to realize our
Panacea Biotec has novel cGMP compliant manufacturing facilities for pharmaceuticals, vaccines, and
biopharmaceuticals. “Development of Pandyflu (Pandemic flu vaccine) within short span of time was
test of our technological, managerial, operative and administrative competency. I am proud that the
company has once again exhibited its strength. We are determined to continuously reinvent ourselves
and fuelling innovation engine for growth,” said Dr Jain.
Panacea Biotec has set up a new BSL2 level manufacturing unit (high-containment facility) with BSL
3 practices in Punjab for manufacturing of Pandyflu with an annual capacity of 4.5 crore doses. This
would enable the company to supply the vaccine globally.